Date recorded: July 26 2016
Duration: 47 minutes 45 seconds
Understanding the stability of biological formulations – including their propensity to aggregate - is one of the primary requirements of moving drug candidates through the development pipeline. Biopharmaceutical companies will often establish a target molecule profile, with the intention of ensuring that poor candidates are removed from the development process as early as possible.
Formulation stability and aggregation potential are core properties for the target molecule profile, to ensure an acceptable drug shelf life, good efficacy and safety profiles, and to minimize the risk of unwanted particle formation.
This presentation introduces the complementary nature of Taylor Dispersion Analysis (TDA) as a method of measuring protein size and understanding the aggregation potential of a biological formulation.